Quantcast

GlaxoSmithKline PLC (GSK)

GSK 
$41
*  
0.78
1.94%
Get GSK Alerts
*Delayed - data as of Jun. 19, 2019  -  Find a broker to begin trading GSK now
Exchange:NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

GlaxoSmithKline PLC (GSK)

Q3 2018 Results Earnings Conference Call

October 31, 2018 10:30 AM ET

Executives

Sarah Elton-Farr - Head of Investor Relations

Emma Walmsley - Chief Executive Officer

Luke Miels - President of Global Pharmaceuticals

David Redfern - Chief Strategy Officer and Chairman of ViiV

Simon Dingemans - Chief Financial Officer.

Analysts

Michael Leuchten - UBS

Kerry Holford - Exane BNP Paribas

Graham Parry - Bank of America Merrill Lynch

Tim Anderson - Wolf Research

Andrew Baum - Citi

Steve Scala - Cowen

James Gordon - JPMorgan

Jo Walton - Credit Suisse

Presentation

Operator

Good afternoon, ladies and gentlemen, and welcome to the GSK Quarter Three 2018 Results call.

I'll now hand you over to Sarah Elton-Farr, Head of Investor Relations, who will introduce today's session. Please proceed.

Sarah Elton-Farr

Good morning, and good afternoon, everyone. Thank you for joining us to discuss our Q3 2018 results, which were issued earlier today. You should have received our press release and can view the presentation on GSK's website. For those not able to view the webcast, slides that accompanies today's call are located on the Investors section of our website. Before we begin, please refer to Slide 2 of our presentation for our cautionary statements.

Our speakers today are Chief Executive Officer, Emma Walmsley; Luke Miels, President of Global Pharmaceuticals; David Redfern, Chief Strategy Officer and Chairman of ViiV; and Simon Dingemans, Chief Financial Officer.

Following our presentation, we will open the call to questions and answers. We request that you ask only a maximum of two questions so that everyone has a chance to participate. Joining us for Q&A are Dr. Hal Barron, Chief Scientific Officer and President of R&D; and Brian McNamara, CEO of our Consumer Healthcare Business.

And with that, I'll hand the call over to Emma.

Emma Walmsley

Thank you, Seth. So overall, Q3 was another good quarter of progress for GSK with improvements in sales, the group operating margin, earnings per share and cash flow. Group's sales growth of 6% in CER terms, reflected sales growth in all three of our global businesses. Our Pharma business grew at 3% CER during the quarter, driven by HIV, and growth of new respiratory products. Our new respiratory portfolio grew at 40% CER, including a GBP 42 million contribution from Trelegy, which continues to see good traction.

In HIV, we also continued to deliver double-digit growth, driven by sales of our dolutegravir portfolio, including Juluca, the first of our new two drug regiments. Benlysta has also become a contributor to growth and grew at 31% CER. Vaccine sales were up 17% CER with continued strong demand for Shingrix, and for which sales are now expected to be GBP 700 million to GBP 750 million for the full year, as well as growth of the meningitis vaccine, Bexsero.

And in Consumer Healthcare, we delivered 3% growth with growth in wellness oral health and nutrition. We’re making very good progress on margin improvements within our Consumer Healthcare business, and this quarter, operating margins reached 22%, an increase of 250 basis points in CER terms compared to this quarter last year, reflecting continued manufacturing, restructuring and integration benefits and improved product mix as well as strong cost control.

Group operating margin this quarter were up 20 basis points on a CER basis, reflecting a more favorable mix of business and continued tight control of ongoing costs, which offset the investments we’re making in the business.

Adjusted earnings were up 14% CER, ahead of operating profit growth, primarily as a result of low minority charges due to our acquisition of Novartis stake in consumer health JV, as well as the reduced adjusted tax rate. On a total reported basis, EPS were up 23% CER to 28.8 pence.

Our free cash flow position also continued to improve. And for the year-to-date, was almost GBP 2.4 billion, up 42% versus the same period last year. We continue to expect to pay a dividend of 80 pence for the full year 2018.

And based on the results we've achieved to date, we are now tightening our guidance towards the upper end of the range for the full year, expecting adjusted EPS growth of 8% to 10% at constant exchange rate. And we expect to maintain this guidance range in the event that the generic version of Advair is introduced before year end.

As you know, I set out three long-term priorities for the business when I became CEO, innovation, performance and trust, all to be underpinned with a necessary shift in our culture. And we’ve made some progress on each priority this quarter. On innovation, Howard laid out that his new approach to R&D at our Q2 results, and he has made some really important changes to his organization with the new governance framework in place, a new head of development, a dedicated head of research and end-to-end oncology and global health R&D units.

We’ve also had some positive development in our pipeline this quarter. We continued to progress our two drug regimens in HIV, making regulatory filings in the U.S and Europe on the back of the positive GEMINI data for the combination of dolutegravir and lamivudine, and now also have had positive results from the pivotal ATLAS and FLAIR studies for a long-acting injectable HIV therapy. We started the first study of BCMA and second-line treatment of multiple myeloma. We've presented some encouraging Phase II data on our anti-GM-CSF compound at the ACR conference last week. And we've seen the first results from an ICOS study which will there earlier we need to see more evidence, showed some initial indications of activity.

We have clearly said we will be more decisive with our pipeline. And this quarter we've also decided to terminate five development programs. These decisions were data driven, primarily based on interim analysis, will allow us to focus our assets on other assets with greater chance of becoming important medicines. Strengthening the pipeline remains a clear priority for the group.

Moving to performance, we continue to make good progress across the business. Investments in prioritization to improve our commercial performance are being reflected in new product sales growth, and we’re moving ahead with the restructuring program we announced at Q2. In addition to the recently announced changes to our supply chain, we've already made some significant changes to our U.S. operations.

Read the rest of this transcript on seekingalpha.com